Poxel (BATS-CHIXE:POXELp) - Stock Price, News & Analysis

POXELp Stock Overview

A clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. More details

POXELp fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Revenue is forecast to grow 52.88% per year

Risk Analysis

Earnings are forecast to decline by an average of 8.3% per year for the next 3 years

Makes less than USD$1m in revenue (€206K)

Negative shareholders equity

Shares are highly illiquid

+ 3 more risks

Poxel S.A. Competitors

OptiBiotix Health

AIM:OPTI

UK£12.5m

Hemogenyx Pharmaceuticals

LSE:HEMO

UK£13.1m

Aptamer Group

AIM:APTA

UK£6.1m

ProBiotix Health

OFEX:PBX

UK£10.7m

Price History & Performance

Summary of all time highs, changes and price drops for Poxel
Historical stock prices
Current Share Price	€1.05
52 Week High	€1.54
52 Week Low	€1.05
Beta	1.39
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-79.53%
5 Year Change	-83.30%
Change since IPO	-92.60%

Recent updates

Shareholder Returns

	POXELp	GB Biotechs	GB Market
7D	0%	1.5%	2.2%
1Y	n/a	-17.9%	8.8%

Return vs Industry: Insufficient data to determine how POXELp performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how POXELp performed against the UK Market.

Price Volatility

Is POXELp's price volatile compared to industry and market?
POXELp volatility
POXELp Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: POXELp has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine POXELp's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	55	Thomas Kuhn	www.poxelpharma.com

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH).

Poxel S.A. Fundamentals Summary

How do Poxel's earnings and revenue compare to its market cap?
POXELp fundamental statistics
Market cap	€22.68m
Earnings (TTM)	-€29.15m
Revenue (TTM)	€206.00k

110.1x

P/S Ratio

-0.8x

P/E Ratio

Is POXELp overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
POXELp income statement (TTM)
Revenue	€206.00k
Cost of Revenue	€142.00k
Gross Profit	€64.00k
Other Expenses	€29.22m
Earnings	-€29.15m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Mar 22, 2023

Earnings per share (EPS)	-1.01
Gross Margin	31.07%
Net Profit Margin	-14,151.94%
Debt/Equity Ratio	-907.3%

How did POXELp perform over the long term?

See historical performance and comparison

Poxel BATS-CHIXE:POXELp Stock Report